Age at diagnosis, years
|
46.0 ± 14.1
|
Age at recruitment, years
|
57.4 ± 12.3
|
Follow-up duration, years
|
3.4 ± 1.7
|
Sex
|
Male
|
148 (13.0 %)
|
Female
|
992 (87.2 %)
|
Race
|
White
|
1012 (93.3 %)
|
Asian
|
50 (4.7 %)
|
Australian Aboriginal or Torres Strait Islander
|
14 (1.3 %)
|
Other
|
9 (0.9 %)
|
Disease duration at recruitmenta
|
11.3 ± 9.9
|
≤ 2 years
|
163 (14.3 %)
|
≤ 5 years
|
356 (31.2 %)
|
Disease subtypeb
|
Diffuse
|
310 (27.2 %)
|
Limited
|
830 (72.8 %)
|
Overlap disease features present everc
|
267 (23.4 %)
|
Rheumatoid arthritis
|
22 (1.9 %)
|
Polymyositis
|
6 (0.5 %)
|
Dermatomyositis
|
1 (0.01 %)
|
Sjögren’s syndrome
|
21 (1.8 %)
|
SLE
|
9 (0.8 %)
|
Serological profile at recruitment
|
Anti-centromere ANA
|
517 (46.2 %)
|
Anti-Scl-70 antibodies
|
167 (15.2 %)
|
Anti-RNAP antibodies
|
84 (13.3 %)
|
Anti-U1 RNP antibodies
|
22 (2.0 %)
|
Anti-Ro antibodies
|
72 (6.6 %)
|
Anti-La antibodies
|
18 (1.6 %)
|
Anti-Sm antibodies
|
6 (0.6 %)
|
Anti-PM-Scl antibodies
|
15 (1.4 %)
|
Anti-dsDNA antibodies
|
26 (3.1 %)
|
Anti-Jo-1 antibodies
|
5 (0.5 %)
|
ANCA
|
134 (12.9 %)
|
MPO specificity
|
17 (1.6 %)
|
PR-3 specificity
|
22 (2.1 %)
|
Rheumatoid factor
|
288 (27.2 %)
|
Anti-phospholipid antibodies
|
272 (25.7 %)
|
Cardiolipin IgM
|
165 (65.0 %)
|
Cardiolipin IgG
|
105 (39.3 %)
|
Anti-β2-glycoprotein antibody
|
84 (33.0 %)
|
Lupus anticoagulant
|
26 (3.1 %)
|